MX2019003970A - Péptidos de arginasa inmunogénicos. - Google Patents

Péptidos de arginasa inmunogénicos.

Info

Publication number
MX2019003970A
MX2019003970A MX2019003970A MX2019003970A MX2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A
Authority
MX
Mexico
Prior art keywords
peptides
immunogenic
arginase
immunogenic arginase
fragments
Prior art date
Application number
MX2019003970A
Other languages
English (en)
Spanish (es)
Inventor
Hald Andersen Mads
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of MX2019003970A publication Critical patent/MX2019003970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019003970A 2016-10-07 2017-10-06 Péptidos de arginasa inmunogénicos. MX2019003970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16192794 2016-10-07
PCT/EP2017/075443 WO2018065563A1 (en) 2016-10-07 2017-10-06 Immunogenic arginase peptides

Publications (1)

Publication Number Publication Date
MX2019003970A true MX2019003970A (es) 2019-12-05

Family

ID=57123856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003970A MX2019003970A (es) 2016-10-07 2017-10-06 Péptidos de arginasa inmunogénicos.

Country Status (18)

Country Link
US (3) US10858642B2 (enExample)
EP (2) EP4406613A3 (enExample)
JP (1) JP7211938B2 (enExample)
KR (1) KR102674521B1 (enExample)
CN (1) CN109890399A (enExample)
AU (1) AU2017341112B2 (enExample)
DK (1) DK3522905T3 (enExample)
ES (1) ES2992031T3 (enExample)
FI (1) FI3522905T3 (enExample)
HR (1) HRP20241486T1 (enExample)
HU (1) HUE069077T2 (enExample)
IL (1) IL265805B2 (enExample)
LT (1) LT3522905T (enExample)
MX (1) MX2019003970A (enExample)
PL (1) PL3522905T3 (enExample)
PT (1) PT3522905T (enExample)
SI (1) SI3522905T1 (enExample)
WO (1) WO2018065563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3522905T3 (pl) 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
GB201815549D0 (en) * 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
US20250161422A1 (en) 2022-02-24 2025-05-22 Io Biotech Aps Arginase 2 vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
WO2003038444A2 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
CA2836155A1 (en) 2004-10-29 2006-05-11 Board Of Trustees Of Michigan State University Protection against herbivores
PL3064579T3 (pl) 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
EP3137103B1 (en) 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PL3522905T3 (pl) * 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
CN109890838A (zh) * 2016-10-27 2019-06-14 Io生物技术公司 新的pdl2化合物

Also Published As

Publication number Publication date
WO2018065563A1 (en) 2018-04-12
EP4406613A3 (en) 2024-10-23
HUE069077T2 (hu) 2025-02-28
JP2019537562A (ja) 2019-12-26
CA3039510A1 (en) 2018-04-12
CN109890399A (zh) 2019-06-14
HRP20241486T1 (hr) 2025-01-03
JP7211938B2 (ja) 2023-01-24
SI3522905T1 (sl) 2025-02-28
PL3522905T3 (pl) 2025-01-07
KR102674521B1 (ko) 2024-06-11
US11981944B2 (en) 2024-05-14
IL265805B2 (en) 2024-08-01
KR20190077381A (ko) 2019-07-03
IL265805B1 (en) 2024-04-01
AU2017341112B2 (en) 2024-06-27
EP3522905B1 (en) 2024-09-25
US20210139877A1 (en) 2021-05-13
EP3522905A1 (en) 2019-08-14
EP4406613A2 (en) 2024-07-31
US20190338270A1 (en) 2019-11-07
US20240167013A1 (en) 2024-05-23
PT3522905T (pt) 2024-10-02
AU2017341112A1 (en) 2019-05-02
FI3522905T3 (fi) 2024-10-31
DK3522905T3 (da) 2024-10-21
LT3522905T (lt) 2024-11-11
IL265805A (en) 2019-06-30
US10858642B2 (en) 2020-12-08
ES2992031T3 (es) 2024-12-05

Similar Documents

Publication Publication Date Title
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
ZA201904725B (en) Personalised immunogenic peptide identification platform
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
EP4218785A3 (en) Mitochondria-targeting peptides
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX361259B (es) Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
EP4406613A3 (en) Immunogenic arginase peptides
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
GEAP202114756A (en) Combination therapy for the treatment of cancer
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
WO2014151369A3 (en) Stabilized ezh2 peptides
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EP3164412A4 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12017500742A1 (en) Statherin peptides
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
PH12019500344A1 (en) Immunotherapy for polyomaviruses
MX2017007740A (es) Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
WO2016150415A8 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
ZA202201468B (en) Method